|
gptkbp:instanceOf
|
gptkb:vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:alsoKnownAs
|
gptkb:Oxford–AstraZeneca_COVID-19_vaccine
gptkb:AZD1222
gptkb:Covishield
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:India
gptkb:United_Kingdom
gptkb:World_Health_Organization
|
|
gptkbp:category
|
gptkb:COVID-19_vaccines
AstraZeneca products
Viral vector vaccines
|
|
gptkbp:clinicalTrialPhase
|
2020
|
|
gptkbp:contains
|
SARS-CoV-2 spike protein gene
|
|
gptkbp:developedBy
|
gptkb:University_of_Oxford
gptkb:AstraZeneca
gptkb:Serum_Institute_of_India
|
|
gptkbp:dosesRequired
|
2
|
|
gptkbp:efficacyAgainstSymptomaticCOVID19
|
60–80%
|
|
gptkbp:emergencyServices
|
December 2020
|
|
gptkbp:intervalBetweenDoses
|
4 to 12 weeks
|
|
gptkbp:introducedIn
|
gptkb:United_Kingdom
|
|
gptkbp:manufacturer
|
gptkb:SK_Bioscience
gptkb:AstraZeneca
gptkb:Serum_Institute_of_India
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
rare blood clotting events
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:technology
|
recombinant DNA
|
|
gptkbp:type
|
gptkb:viral_vector_vaccine
|
|
gptkbp:vectorFor
|
gptkb:chimpanzee_adenovirus
|
|
gptkbp:WHOEmergencyUseListing
|
February 2021
|
|
gptkbp:bfsParent
|
gptkb:Oxford–AstraZeneca_COVID-19_vaccine
gptkb:COVID-19_vaccine_(Vaxzevria)
gptkb:Vaxzevria
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ChAdOx1 nCoV-19
|